Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.36 |
| ▸ | RAF1 | P04049 | 16/20 | 0.33 |
| ▸ | BRAF | P15056 | 16/20 | 0.33 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.33 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.33 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23994834 | 0.94 | NT5E (0.38) | NT5ERAF1BRAF | |
| SCHEMBL23994833 | 0.94 | NT5E (0.38) | NT5ERAF1BRAF | |
| SCHEMBL23995425 | 0.93 | NT5E (0.37) | NT5ERAF1BRAF | |
| SCHEMBL23993089 | 0.91 | NT5E (0.36) | NT5ERAF1BRAF | |
| SCHEMBL23993292 | 0.90 | NT5E (0.37) | NT5ERAF1BRAFIP6K1IP6K3 | |
| SCHEMBL23994454 | 0.90 | NT5E (0.37) | NT5ERAF1BRAFIP6K1IP6K3 | |
| SCHEMBL25004243 | 0.89 | NT5E (0.38) | NT5ERAF1BRAF | |
| SCHEMBL23994437 | 0.89 | NT5E (0.38) | NT5ERAF1BRAF | |
| SCHEMBL23993788 | 0.89 | NT5E (0.36) | NT5E | |
| SCHEMBL23994424 | 0.88 | SYK (0.40) | NT5ERAF1BRAFPIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110294-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| EP-4143194-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | NT5E 3/4885RAF1 2499/4885BRAF 1019/4885 |
| US-12110294-B2 | CD73 compounds | ENTPD5, ENTPD1, NT5E | NT5E 3/4885RAF1 2556/4885BRAF 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.